Karyopharm Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA for accelerated approval of XPOVIO in combination with ruxolitinib for myelofibrosis, requesting Priority Review. This filing, based on Phase 3 SENTRY trial data, could significantly expand XPOVIO's market if approved, representing a major potential revenue driver for the company.
Karyopharm Therapeutics (KPTI) has submitted an sNDA to the FDA for accelerated approval of XPOVIO for myelofibrosis, a significant step towards expanding the drug's indications. This matters because accelerated approval, especially with Priority Review, could bring the drug to market much faster, potentially generating substantial new revenue for KPTI. The company expects the FDA to consider spleen volume reduction as a surrogate endpoint for overall survival, which is a key factor for accelerated approval. This news is a strong positive catalyst for KPTI in the short term, as it signals progress towards a new market opportunity, and long-term, successful approval and commercialization would significantly enhance the company's financial outlook. The main risk is that the FDA may not grant accelerated approval or Priority Review, or may not agree on the surrogate endpoint, which could delay or prevent market entry.